• COLO320DM人结直肠腺癌细胞(STR鉴定正确)

    价 格:¥1800

    期 货:现货(冻存管发2支)

    保藏中心:BTCC

    资源编号:BTCC-1045

    产地🤸🏻‍♀️:中国

    套 餐:

    T25/复苏细胞 无血清冻存液 专用完全培养基500ml 南美特级胎牛血清500ml

    详细资料说明书下载质检报告(COA)

    Cell line nameCOLO 320DM
    SynonymsCOLO-320DM; COLO_320DM; COLO-320-DM; COLO #320DM; COLO320/DM; COLO320-DM; COLO320DM; Colo320DM; COLO320 DM; COLO 320 DM; COLO 320 (DM); Colorado 320 Double Minutes
    AccessionBTCC-1045
    Resource Identification InitiativeTo cite this cell line use: COLO 320DM (BTCC-1045)
    CommentsPart of: AstraZeneca Colorectal cell line (AZCL) panel.
    Part of: MD Anderson Cell Lines Project.
    Population: Caucasian.
    Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
    Omics: Deep proteome analysis.
    Omics: Protein expression by reverse-phase protein arrays.
    Omics: SNP array analysis.
    Omics: Transcriptome analysis by microarray.
    Omics: Transcriptome analysis by RNAseq.
    Misspelling: COLD-320-DM; Cosmic=1466812.
    Derived from site: In situ; Colon, sigmoid; UBERON=UBERON_0001159.
    Sequence variations
    HLA typingSource: PubMed=26589293
    Class I
    HLA-AA*24:02,24:02
    HLA-BB*14:02,39:10
    HLA-CC*08:02,08:02
    DiseaseColon adenocarcinoma (NCIt: C4349)
    Species of originHomo sapiens (Human) (NCBI Taxonomy: 9606)
    HierarchyParent: CVCL_1989 (COLO 320)
    Children:



    CVCL_XD07 (COLO 320DM-EGFP)CVCL_XD08 (COLO 320DM-RFP)CVCL_A6UJ (COLO 320DM#3)
    CVCL_A6UK (COLO 320DM#3 SIRT1 KO cl.1)CVCL_A6UL (COLO 320DM#3 SIRT1 KO cl.2)CVCL_A6UM (COLO 320DM#3 SIRT1 KO cl.3)
    CVCL_A6UN (COLO 320DM#3 SIRT1 KO cl.4)CVCL_A6UP (COLO 320DM#3 SIRT1 KO cl.5)CVCL_A6UQ (COLO 320DM#3 SIRT1 KO cl.6)
    CVCL_1990 (COLO 320DMF)CVCL_0220 (COLO 320HSR)CVCL_F641 (COLO 587)
    Sex of cellFemale
    Age at sampling55Y
    CategoryCancer cell line
    STR profileSource(s): ATCC; CCRID; CLS; ECACC; JCRB; KCLB; PubMed=25877200; PubMed=25926053

    Markers:
    AmelogeninX
    CSF1PO11 (ATCC; CCRID; CLS; JCRB; KCLB; PubMed=25877200; PubMed=25926053)
    11,12 (ECACC)
    D2S133818,25
    D3S135817
    D5S81812
    D7S8209,12
    D8S117913
    D13S31711
    D16S53911,12
    D18S5115
    D19S43316.2
    D21S1131,33.2 (PubMed=25926053)
    33.2 (CCRID; CLS; PubMed=25877200)
    FGA20
    Penta D9,12
    Penta E11
    TH018,9 (ECACC)
    9 (ATCC; CCRID; CLS; JCRB; KCLB; PubMed=25877200; PubMed=25926053)
    TPOX8,9
    vWA15,18

    Run an STR similarity search on this cell line
    Web pageshttps://tcpaportal.org/mclp/
    Publications

    PubMed=498117
    Quinn L.A., Moore G.E., Morgan R.T., Woods L.K.
    Cell lines from human colon carcinoma with unusual cell products, double minutes, and homogeneously staining regions.
    Cancer Res. 39:4914-4924(1979)

    PubMed=3164477; DOI=10.1073/pnas.85.13.4804
    Von Hoff D.D., Needham-VanDevanter D.R., Yucel J., Windle B.E., Wahl G.M.
    Amplified human MYC oncogenes localized to replicating submicroscopic circular DNA molecules.
    Proc. Natl. Acad. Sci. U.S.A. 85:4804-4808(1988)

    PubMed=7874267; DOI=10.1007/BF02349278
    Ikuta S., Itoh F., Hinoda Y., Toyota M., Makiguchi Y., Imai K., Yachi A.
    Expression of cytoskeletal-associated protein tyrosine phosphatase PTPH1 mRNA in human hepatocellular carcinoma.
    J. Gastroenterol. 29:727-732(1994)

    PubMed=7651727
    Kastrinakis W.V., Ramchurren N., Rieger K.M., Hess D.T., Loda M., Steele G., Summerhayes I.C.
    Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
    Oncogene 11:647-652(1995)

    PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::aid-mc5>3.0.CO;2-D
    Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
    Screening the p53 status of human cell lines using a yeast functional assay.
    Mol. Carcinog. 19:243-253(1997)

    PubMed=16418264; DOI=10.1073/pnas.0510146103
    Liu Y., Bodmer W.F.
    Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines.
    Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006)

    PubMed=18258742; DOI=10.1073/pnas.0712176105
    Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
    Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
    Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008)

    PubMed=19927377; DOI=10.1002/gcc.20730
    Knutsen T., Padilla-Nash H.M., Wangsa D., Barenboim-Stapleton L., Camps J., McNeil N.E., Difilippantonio M.J., Ried T.
    Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines.
    Genes Chromosomes Cancer 49:204-223(2010)

    PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
    Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
    A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
    Cancer Res. 70:2158-2164(2010)

    PubMed=20606684; DOI=10.1038/sj.bjc.6605780
    Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
    5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
    Br. J. Cancer 103:340-346(2010)

    PubMed=22538498; DOI=10.1159/000338793
    Grozinsky-Glasberg S., Shimon I., Rubinfeld H.
    The role of cell lines in the study of neuroendocrine tumors.
    Neuroendocrinology 96:173-187(2012)

    PubMed=23272949; DOI=10.1186/1755-8794-5-66
    Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A., Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A., Orphanides G., French T., Wessels L.F.A.
    Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
    BMC Med. Genomics 5:66.1-66.15(2012)

    PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013
    Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S., Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S., O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F., Mariadason J.M., Sieber O.M.
    Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
    Cancer Res. 74:3238-3247(2014)

    PubMed=25485619; DOI=10.1038/nbt.3080
    Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
    A comprehensive transcriptional portrait of human cancer cell lines.
    Nat. Biotechnol. 33:306-312(2015)

    PubMed=25926053; DOI=10.1038/ncomms8002
    Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G., Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S., Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M., Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
    The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
    Nat. Commun. 6:7002.1-7002.10(2015)

    PubMed=26589293; DOI=10.1186/s13073-015-0240-5
    Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
    TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
    Genome Med. 7:118.1-118.7(2015)

    PubMed=28179481; DOI=10.1158/1535-7163.MCT-16-0578
    Tanaka N., Mashima T., Mizutani A., Sato A., Aoyama A., Gong B., Yoshida H., Muramatsu Y., Nakata K., Matsuura M., Katayama R., Nagayama S., Fujita N., Sugimoto Y., Seimiya H.
    APC mutations as a potential biomarker for sensitivity to tankyrase inhibitors in colorectal cancer.
    Mol. Cancer Ther. 16:752-762(2017)

    PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
    Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
    Characterization of human cancer cell lines by reverse-phase protein arrays.
    Cancer Cell 31:225-239(2017)

    PubMed=29101300; DOI=10.15252/msb.20177701
    Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S., Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S., Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J., Weichert W., Knapp S., Feller S.M., Kuster B.
    Pharmacoproteomic characterisation of human colon and rectal cancer.
    Mol. Syst. Biol. 13:951-951(2017)

    Cross-references
    Cell line databases/resourcesCLO; CLO_0002546
    MCCL; MCC:0000108
    CLDB; cl827
    CCRID; 1101HUM-PUMC000133
    CCRID; 3101HUMTCHu208
    ColonAtlas; COLO320DM
    LINCS_LDP; LCL-1197
    SKY/M-FISH/CGH; 5014
    TOKU-E; 985
    Biological sample resourcesBioSample; SAMN03471612
    Cell line collections (Providers)ATCC; CCL-220
    BCRC; 60108
    CCTCC; GDC0042
    CLS; 300153
    ECACC; 87061205
    JCRB; JCRB0225
    KCB; KCB 200694YJ
    KCLB; 10220
    Chemistry resourcesChEMBL-Cells; CHEMBL3307647
    ChEMBL-Targets; CHEMBL614562
    PharmacoDB; COLO320DM_216_2019
    PubChem_Cell_line; CVCL_0219
    Encyclopedic resourcesWikidata; Q54814089
    Experimental variables resourcesEFO; EFO_0002136

    更多>>相关产品

    总部地址:北京市怀柔区渤海镇怀沙路536号

    关注杏鑫
    在线咨询
    在线客服
    电话咨询
    微信客服
    返回顶部
    杏鑫娱乐专业提供:杏鑫娱乐杏鑫⚒、杏鑫平台等服务,提供最新官网平台、地址、注册、登陆、登录、入口、全站、网站、网页、网址、娱乐、手机版、app、下载、欧洲杯、欧冠、nba、世界杯、英超等,界面美观优质完美,安全稳定,服务一流,杏鑫娱乐欢迎您。